

## Company Description

OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI's mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4) and AKR1C3. Globo Series and AKR1C3 are highly expressed in cancers of unmet need including Breast, Ovarian, Gastric, Lung, Liver Prostate and Esophageal. The company's novel first-in-class oncology portfolio includes: Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine), OBI-888 (Globo H mAb), OBI-999 (Globo H ADC), OBI-898 (SSEA4 mAb), OBI-866 (SSEA4 cancer vaccine), and OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme).

## Contact Information

<b>Name</b>	<b>Kevin Poulos</b>	<b>Position</b>	Chief Commercial Officer
<b>Tel</b>	<b>+001-619-537-7698</b>		
<b>E-mail</b>	<b>kpoulos@obipharmausa.com</b>		
<b>Address</b>	7F, No. 369, Sec. 7, Zhongxiao E Rd, Nangang Dist., Taipei City 115, Taiwan (R.O.C)		
<b>Sectors</b>	Biopharmaceutical, New Drug Development, Oncology, Immu-no-oncology, Novel Cancer Therapeutics		